SEC Form 4 · accession 0001209191-18-004594
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Alan Goldberg
Director
Period of report
Jan 1, 2018
Accepted (ET)
Jan 19, 2018 · 5:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $33.91 | Jan 1, 2018 | A | 18,000 | A | — | Jan 1, 2028 | Common Stock | 18,000 | 18,000 | D |
| Stock Option (right to buy)F1 | $38.00 | Jan 18, 2018 | A | 4,500 | A | — | Jan 18, 2028 | Common Stock | 4,500 | 4,500 | D |
Explanation of responses
- F1The option vests as to 2.777% of the total shares monthly, beginning on January 11, 2018, with 100% of the total shares vested and exercisable on December 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date.